Q4 2026
Next results · Q4 2026Projected
Mar 2, before the open
Tue, Mar 2, 2027in 105 days
Projected from its last 8 releases. The company has not named the day yet.
- Quarter
- Q4 2026 · Ends about Dec 31, 2026
- 10-K window
- Feb 25 – Mar 12
Read against Q4 2025
The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.
- Revenue
- $838.00K
- Revenue, change from a year earlier: Q3 2026 +243.9%, Q4 2025 −61.6%, Q3 2025 +486.1%, Q2 2025 n/m
- Net income
- -$46.08M
- Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
- EPS
- —
- EPS, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m
Results day
Typical moveA typical move of 7.8% either way
Up after 4 of 12, down after 8.
The stock’s move from the last close before each release to the first close after it, over the last 12 releases. Largest: +10.4% after Q3 2026.
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
When it reports
- Usual day
- Varies
- Session
- before the open
- After quarter end
- 37 to 59 days
- 10-Q filed
- 37 to 43 days
- over its last 8
- 10-K filed
- 59 to 68 days
- over its last 4
Based on 4 prior 10-K filings.
Prime Medicine, Inc. · CIK 1894562 · Engraved from SEC EDGAR